Caricamento...
Early changes in rpS6 phosphorylation and BH3 profiling predict response to chemotherapy in AML cells
Blasts from different patients with acute myeloid leukemia (AML) vary in the agent(s) to which they are most responsive. With a myriad of novel agents to evaluate, there is a lack of predictive biomarkers to precisely assign targeted therapies to individual patients. Primary AML cells often survive...
Salvato in:
| Pubblicato in: | PLoS One |
|---|---|
| Autori principali: | , , , , , , |
| Natura: | Artigo |
| Lingua: | Inglês |
| Pubblicazione: |
Public Library of Science
2018
|
| Soggetti: | |
| Accesso online: | https://ncbi.nlm.nih.gov/pmc/articles/PMC5933738/ https://ncbi.nlm.nih.gov/pubmed/29723246 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1371/journal.pone.0196805 |
| Tags: |
Aggiungi Tag
Nessun Tag, puoi essere il primo ad aggiungerne! !
|